Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α

Simple item page
buir.contributor.authorCeran, Ceyhan
buir.contributor.authorTaşan, İpek
buir.contributor.authorÖztürk, Mehmet
buir.contributor.authorYağcı, Tamer
dc.citation.epage16en_US
dc.citation.issueNumber450en_US
dc.citation.spage1en_US
dc.citation.volumeNumber12en_US
dc.contributor.authorCeran, Ceyhanen_US
dc.contributor.authorÇokol, M.en_US
dc.contributor.authorCingöz, S.en_US
dc.contributor.authorTaşan, İpeken_US
dc.contributor.authorÖztürk, Mehmeten_US
dc.contributor.authorYağcı, Tameren_US
dc.date.accessioned2020-04-14T09:36:39Z
dc.date.available2020-04-14T09:36:39Z
dc.date.issued2012
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.departmentGenetics and Biotechnology Research Center (BİLGEN)en_US
dc.description.abstractBackground: One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an epitope on subdomain IV of the extracellular domain of HER2 is used for therapy of HER2-overexpressing mammary tumors. However, many tumors are either natively resistant or acquire resistance against Trastuzumab. Antibodies directed to different epitopes on the extracellular domain of HER2 are promising candidates for replacement or combinatorial therapy. For example, Pertuzumab that binds to subdomain II of HER2 extracellular domain and inhibits receptor dimerization is under clinical trial. Alternative antibodies directed to novel HER2 epitopes may serve as additional tools for breast cancer therapy. Our aim was to generate novel anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer cells, either alone or in combination with tumor necrosis factor-α (TNF-α). Methods: Mice were immunized against SK-BR-3 cells and recombinant HER2 extracellular domain protein to produce monoclonal antibodies. Anti-HER2 antibodies were characterized with breast cancer cell lines using immunofluorescence, flow cytometry, immunoprecipitation, western blot techniques. Antibody epitopes were localized using plasmids encoding recombinant HER2 protein variants. Antibodies, either alone or in combination with TNF-α, were tested for their effects on breast cancer cell proliferation. Results: We produced five new anti-HER2 monoclonal antibodies, all directed against conformational epitope or epitopes restricted to the native form of the extracellular domain. When tested alone, some antibodies inhibited modestly but significantly the growth of SK-BR-3, BT-474 and MDA-MB-361 cells displaying ERBB2 amplification. They had no detectable effect on MCF-7 and T47D cells lacking ERBB2 amplification. When tested in combination with TNF-α, antibodies acted synergistically on SK-BR-3 cells, but antagonistically on BT-474 cells. A representative anti-HER2 antibody inhibited Akt and ERK1/2 phosphorylation leading to cyclin D1 accumulation and growth arrest in SK-BR-3 cells, independently from TNF-α. Conclusions: Novel antibodies against extracellular domain of HER2 may serve as potent anti-cancer bioactive molecules. Cell-dependent synergy and antagonism between anti-HER2 antibodies and TNF-α provide evidence for a complex interplay between HER2 and TNF-α signaling pathways. Such complexity may drastically affect the outcome of HER2-directed therapeutic interventions.en_US
dc.identifier.doi10.1186/1471-2407-12-450en_US
dc.identifier.issn1471-2407
dc.identifier.urihttp://hdl.handle.net/11693/53616
dc.language.isoEnglishen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofhttps://doi.org/10.1186/1471-2407-12-450en_US
dc.source.titleBMC Canceren_US
dc.subjectHER2en_US
dc.subjectERBB2en_US
dc.subjectTNF-αen_US
dc.subjectMonoclonal antibodiesen_US
dc.subjectEpitope mappingen_US
dc.subjectGrowth inhibitionen_US
dc.subjectBreast canceren_US
dc.subjectSynergyen_US
dc.subjectAntagonismen_US
dc.titleNovel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-αen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Novel_anti_HER2_monoclonal_antibodies_synergy_and_antagonism_with_tumor_necrosis_factor_α.pdf
Size:
3.87 MB
Format:
Adobe Portable Document Format
Description:
View / Download
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Department of Molecular Biology and Genetics
Genetics and Biotechnology Research Center (BİLGEN)